Researchers at the Duke University, Oswaldo Cruz Foundation, University of Sao Paulo, and Federal University of Paraiba are stating that immunization with a dengue vaccine could be protective against the COVID-19 infection. It has been found that there were several million cases of dengue fever between January 2019 and July 2020 in Brazil. Those regions where people had high antibody levels for dengue fever had low incidences of coronavirus cases, compounded with a low infection rate and mortality. Such findings are keeping economies running in the dengue vaccines market during the pandemic.
As COVID-19 vaccines have been launched in several countries, vaccine safety communication has become more relevant than ever. Companies in the dengue vaccines market are creating awareness about the dengue vaccine controversy of Philippines in 2016 to facilitate efficient inoculation of COVID-19 and other antiviral vaccines.
The development of dengue vaccines is potentially challenging, since the virus has antigenically four different serotypes. Companies in the dengue vaccines market are acquiring a strong research base to develop vaccines that are ideal for all four serotypes at the same time. The complex immunopathology of dengue has led to complications in vaccine development.
Dengue vaccines have also been challenged with critical issues such as lack of animal models for the disease and dearth of suitable markers for protective immunity. Several vaccine candidates are in the pipeline for its development with increased emphasis on live attenuated virus vaccines, subunit vaccines, and live chimeric virus vaccines, among others. As such, the Butantan/Merck vaccine is being highly publicized for containing three full-genomes of the four dengue virus serotypes.
In order to improve tetravalent protection, there has been a growing awareness for sequential vaccination in addition to a heterologous prime-boost approach. Companies in the dengue vaccines market are expected to collaborate with researchers such as at the Singapore-MIT Alliance for Research and Technology (SMART), who are capitalizing on the opportunity to make sequential vaccination more safe and effective than the existing tetravalent vaccine. Due to absence of research in animal models, companies are anticipated to find practical ways to induce strong and broad immunity to the dengue virus based on proof-of-concept studies in mice.
The dengue vaccines market is estimated to advance at a robust CAGR of 11% during the forecast period. Companies are increasing their research on the basis of Dengvaxia, which consists of four variant dengue antigens.
The dengue vaccines market is projected to cross US$ 1.4 Bn by 2031. Takeda - a Japan-based multinational pharmaceutical company has begun its regulatory submissions for dengue vaccine candidate, TAK-003, in the EU (European Union) and dengue-endemic countries including Brazil, Indonesia, and Mexico. Other competitor companies are taking cues from such developments and increasing efforts to conduct parallel assessment of medicinal products to innovate in vaccines.
Companies in the dengue vaccines market are increasing the focus on the development of vaccines that can act in the prevention of dengue in individual ages from four to 60 years. They are unlocking growth opportunities in Malaysia, Thailand, and Singapore, among other countries. This is evident since Asia Pacific is expected to dominate the highest revenue share among all regions in the market during the assessment period.
The commitment to R&D for vaccine development is emerging as one of the most crucial strategies to gain a competitive edge in the dengue vaccines market. Continuous research holds promising potentials for the development of next-gen dengue, malaria, and tuberculosis vaccines. The R&D has become the need of the hour, since greater acceptability, improved production, and cost effectiveness of dengue vaccines are key deciding factors for its success in the market landscape.
The Developing Countries Vaccine Manufacturers Network (DCVMN) is gaining popularity for its growing capacity and willingness to effectively advance vaccine clinical development. Network members linked with the dengue vaccines market are boosting their production capacities to combat high incidence of dengue and other regional infectious diseases in patients.
According to the World Health Organization (WHO), dengue represents one of the 10 biggest global health threats. Panacea Biotec - a global generic and specialty pharmaceutical and vaccine maker registered in India has announced the successful completion of phase I/II study of its novel tetravalent recombinant chimeric dengue candidate vaccine DengiAll. Companies in the dengue vaccines market are taking cues from such news, and making efforts to increase access to safe and effective dengue vaccine candidates to minimize the devastating impact of dengue fever in endemic countries such as Colombia, Sri Lanka, and Argentina.
Companies in the dengue vaccines market are innovating in vaccine candidates that induce robust, balanced, and neutralizing antibody response against all four dengue virus serotypes.
The Department of Biotechnology in India is being highly publicized for making concerted efforts to strengthen vaccine R&D through their Vaccine Action Program. Companies in the India dengue vaccines market are taking advantage of this opportunity to participate in the Human Immunology Project Consortium (HIPC) Collaboration, which is a funding program to promote India-U.S. collaborative R&D on human immunophenotyping in the context of infectious diseases and vaccine development.
India’s market for dengue vaccines is undergoing a critical change with the help of National Expert Groups and Indo-U.S. Vaccine Action Program. Stakeholders are gaining awareness about such collaborative initiatives, which are helping to take major strides toward vaccine development for diseases including malaria and dengue. The International Centre for Genetic Engineering and Biotechnology (ICGEB) involving drug major Sun Pharma is using recombinant EDIII- based sub-unit dengue vaccine candidate to develop injectable vaccines.
Analysts’ Viewpoint
Prior immunization with dengue vaccine holds promising potentials to increase antibodies in individuals and prevent the contraction of the coronavirus infection. Although some vaccine candidates are transitioning from animal trials to phase II and III in humans, several issues regarding dengue vaccine implementation in countries such as India need to be addressed. Thus, companies in the India and global dengue vaccines market should capitalize on collaborative efforts made by regulatory bodies, including the WHO, with policy makers in order to standardize field trials for safe and efficacious dengue vaccines. The Indo-U.S. Vaccine Action Program is gaining increased popularity for improvising the current understanding of vaccine science.
Dengue Vaccines Market – Segmentation
TMR’s study on the global dengue vaccines market includes information divided into five segments: category, product, route of administration, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global dengue vaccines market are discussed in detail.
| Category |
|
| Product |
|
| Route of Administration |
|
| End User |
|
| Region |
|
Dengue vaccines market to surpass valuation of US$ 1.4 Bn by 2031
Dengue vaccines market is projected to expand at a CAGR of 11% from 2021 to 2031
Dengue vaccines market is driven by increase in cases of dengue and continuous evolution of dengue vaccines
The live attenuated vaccines segment is expected to dominate the global dengue vaccines market during the forecast period
Key players operating in the global dengue vaccines market include Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, Merck Co. & Inc., GlaxoSmithKline plc, GeneOne Life Science
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dengue Vaccines Market
4. Market Overview
4.1. Introduction
4.1.1. Category Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dengue Vaccines Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence
5.3. Patient Volume
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Dengue Vaccines Market Analysis and Forecast, by Category
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Category, 2017–2031
6.3.1. Live Attenuated Vaccines
6.3.2. Chimeric Live Attenuated Vaccines
6.3.3. Others
6.4. Market Attractiveness Analysis, by Category
7. Global Dengue Vaccines Market Analysis and Forecasts, by Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Product, 2017–2031
7.3.1. CYD-TDV (Dengvaxia)
7.3.2. Others
7.4. Market Attractiveness Analysis, by Product
8. Global Dengue Vaccines Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Subcutaneous
8.3.2. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Dengue Vaccines Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Government Institutes
9.3.3. Specialty Clinics
9.3.4. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Dengue Vaccines Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Global Dengue Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Category, 2017–2031
11.2.1. Live Attenuated Vaccines
11.2.2. Chimeric Live Attenuated Vaccines
11.2.3. Others
11.3. Market Value Forecast, by Product, 2017–2031
11.3.1. CYD-TDV (Dengvaxia)
11.3.2. Others
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Subcutaneous
11.4.2. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Government Institutes
11.5.3. Specialty Clinics
11.5.4. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Category
11.7.2. By Product
11.7.3. By Route of Administration
11.7.4. By End-user
11.7.5. By Country
12. Europe Global Dengue Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Category, 2017–2031
12.2.1. Live Attenuated Vaccines
12.2.2. Chimeric Live Attenuated Vaccines
12.2.3. Others
12.3. Market Value Forecast, by Product, 2017–2031
12.3.1. CYD-TDV (Dengvaxia)
12.3.2. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Subcutaneous
12.4.2. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Government Institutes
12.5.3. Specialty Clinics
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Category
12.7.2. By Product
12.7.3. By Route of Administration
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Global Dengue Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Category, 2017–2031
13.2.1. Live Attenuated Vaccines
13.2.2. Chimeric Live Attenuated Vaccines
13.2.3. Others
13.3. Market Value Forecast, by Product, 2017–2031
13.3.1. CYD-TDV (Dengvaxia)
13.3.2. Others
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Subcutaneous
13.4.2. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Government Institutes
13.5.3. Specialty Clinics
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Category
13.7.2. By Product
13.7.3. By Route of Administration
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Global Dengue Vaccines Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Category, 2017–2031
14.2.1. Live Attenuated Vaccines
14.2.2. Chimeric Live Attenuated Vaccines
14.2.3. Others
14.3. Market Value Forecast, by Product, 2017–2031
14.3.1. CYD-TDV (Dengvaxia)
14.3.2. Others
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Subcutaneous
14.4.2. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Government Institutes
14.5.3. Specialty Clinics
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Category
14.7.2. By Product
14.7.3. By Route of Administration
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Global Dengue Vaccines Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Category, 2017–2031
15.2.1. Live Attenuated Vaccines
15.2.2. Chimeric Live Attenuated Vaccines
15.2.3. Others
15.3. Market Value Forecast, by Product, 2017–2031
15.3.1. CYD-TDV (Dengvaxia)
15.3.2. Others
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Subcutaneous
15.4.2. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Government Institutes
15.5.3. Specialty Clinics
15.5.4. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Category
15.7.2. By Product
15.7.3. By Route of Administration
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Share Analysis, by Company, 2020
16.2. Company Profiles
16.2.1. Sanofi Pasteur Limited
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Product Portfolio
16.2.1.3. SWOT Analysis
16.2.1.4. Strategic Overview
16.2.2. Takeda Pharmaceutical Company Limited
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Product Portfolio
16.2.2.3. SWOT Analysis
16.2.2.4. Strategic Overview
16.2.3. Merck Co. & Inc.
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Product Portfolio
16.2.3.3. SWOT Analysis
16.2.3.4. Strategic Overview
16.2.4. GlaxoSmithKline plc
16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.4.2. Product Portfolio
16.2.4.3. SWOT Analysis
16.2.4.4. Strategic Overview
16.2.5. GeneOne Life Science
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Product Portfolio
16.2.5.3. SWOT Analysis
16.2.5.4. Strategic Overview
16.2.6. Medigen Vaccine Biologics
16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.6.2. Product Portfolio
16.2.6.3. SWOT Analysis
16.2.6.4. Strategic Overview
16.2.7. Panacea Biotec Limited
16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.7.2. Product Portfolio
16.2.7.3. SWOT Analysis
16.2.7.4. Strategic Overview
16.2.8. Sun Pharmaceutical Industries Ltd.
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Product Portfolio
16.2.8.3. SWOT Analysis
16.2.8.4. Strategic Overview
16.2.9. Serum Institute of India Pvt. Ltd.
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Product Portfolio
16.2.9.3. SWOT Analysis
16.2.9.4. Strategic Overview
16.2.10. Biological E
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Product Portfolio
16.2.10.3. SWOT Analysis
16.2.10.4. Strategic Overview
16.2.11. VabioTech
16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.11.2. Product Portfolio
16.2.11.3. SWOT Analysis
16.2.11.4. Strategic Overview
List of Tables
Table 01: Global Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017–2031
Table 02: Global Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Dengue Vaccines Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017–2031
Table 06: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017–2031
Table 07: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 8: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 09: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 10: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017–2031
Table 11: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017–2031
Table 12: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 13: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 14: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 15: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017–2031
Table 16: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017–2031
Table 17: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 18: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 19: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017–2031
Table 21: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 22: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 23: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 24: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017–2031
Table 25: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017–2031
Table 26: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 27: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 28: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Dengue Vaccines Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Dengue Vaccines Market Value Share, by Category, 2020
Figure 03: Global Dengue Vaccines Market Value Share, by Product, 2020
Figure 04: Global Dengue Vaccines Market Value Share, by End-user, 2020
Figure 05: Global Dengue Vaccines Market Value Share, by Region, 2020
Figure 06: Global Dengue Vaccines Market Value Share, by Route of Administration, 2020
Figure 07: Global Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
Figure 08: Global Dengue Vaccines Market Attractiveness Analysis, by Category, 2021–2031
Figure 09: Global Dengue Vaccines Market Value (US$ Mn), by Live Attenuated Vaccines Category, 2017–2031
Figure 10: Global Dengue Vaccines Market Value (US$ Mn), by Chimeric Live Attenuated Vaccines Category, 2017–2031
Figure 11: Global Dengue Vaccines Market Value (US$ Mn), by Others Category, 2017–2031
Figure 12: Global Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 13: Global Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 14: Global Dengue Vaccines Market Value (US$ Mn), by Subcutaneous, 2017–2031
Figure 15: Global Dengue Vaccines Market Value (US$ Mn), by Others, 2017–2031
Figure 16: Global Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
Figure 17: Global Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021–2031
Figure 18: Global Dengue Vaccines Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 19: Global Dengue Vaccines Market Value (US$ Mn), by Government institutes, 2017–2031
Figure 20: Global Dengue Vaccines Market Value (US$ Mn), by Specialty Clinics, 2017–2031
Figure 21: Global Dengue Vaccines Market Value (US$ Mn), by Others, 2017–2031
Figure 22: Global Dengue Vaccines Market Value Share Analysis, by Region, 2020 and 2031
Figure 23: Global Dengue Vaccines Market Attractiveness Analysis, by Region, 2021–2031
Figure 24: North America Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 25: North America Dengue Vaccines Market Value Share, by Sub-region, 2020–2031
Figure 26: North America Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021–2031
Figure 27: North America Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
Figure 28: North America Dengue Vaccines Market Attractiveness Analysis, by Category, 2021–2031
Figure 29: North America Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
Figure 30: North America Dengue Vaccines Market Attractiveness Analysis, by Product, 2021–2031
Figure 31: North America Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 32: North America Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 33: North America Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
Figure 34: North America Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021–2031
Figure 35: Europe Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 36: Europe Dengue Vaccines Market Value Share, by Sub-region, 2020–2031
Figure 37: Europe Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021–2031
Figure 38: Europe Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
Figure 39: Europe Dengue Vaccines Market Attractiveness Analysis, by Category, 2021–2031
Figure 40: Europe Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
Figure 41: Europe Dengue Vaccines Market Attractiveness Analysis, by Product, 2021–2031
Figure 42: Europe Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 43: Europe Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 44: Europe Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
Figure 45: Europe Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021–2031
Figure 46: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 47: Asia Pacific Dengue Vaccines Market Value Share, by Sub-region, 2020–2031
Figure 48: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021–2031
Figure 49: Asia Pacific Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
Figure 50: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by Category, 2021–2031
Figure 51: Asia Pacific Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
Figure 52: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by Product, 2021–2031
Figure 53: Asia Pacific Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 54: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 55: Asia Pacific Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
Figure 56: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021–2031
Figure 57: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 58: Latin America Dengue Vaccines Market Value Share, by Sub-region, 2020–2031
Figure 59: Latin America Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021–2031
Figure 60: Latin America Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
Figure 61: Latin America Dengue Vaccines Market Attractiveness Analysis, by Category, 2021–2031
Figure 62: Latin America Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
Figure 63: Latin America Dengue Vaccines Market Attractiveness Analysis, by Product, 2021–2031
Figure 64: Latin America Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 65: Latin America Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 66: Latin America Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
Figure 67: Latin America Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021–2031
Figure 68: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 69: Middle East & Africa Dengue Vaccines Market Value Share, by Sub-region, 2020–2031
Figure 70: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021–2031
Figure 71: Middle East & Africa Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
Figure 72: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by Category, 2021–2031
Figure 73: Middle East & Africa Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
Figure 74: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by Product, 2021–2031
Figure 75: Middle East & Africa Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 76: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 77: Middle East & Africa Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
Figure 78: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Dengue Vaccines Market
